Bone Biologics Co. (NASDAQ:BBLG) Sees Significant Decrease in Short Interest

Bone Biologics Co. (NASDAQ:BBLG) was the recipient of a significant decline in short interest in the month of February. As of February 15th, there was short interest totalling 130,400 shares, a decline of 15.9% from the January 31st total of 155,000 shares. Based on an average trading volume of 200,800 shares, the short-interest ratio is presently 0.6 days. Approximately 24.5% of the company’s shares are short sold.

Bone Biologics Stock Performance

Shares of NASDAQ:BBLG opened at $0.84 on Friday. Bone Biologics has a 12 month low of $0.71 and a 12 month high of $4.25. The business has a 50-day moving average of $1.01 and a two-hundred day moving average of $1.30.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.